#1
Posted: Fri Mar 13, 2026 3:40 pm
A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer's disease. Unlike current drugs, which mainly remove beta-amyloid plaques that accumulate in the brain, this new experimental drug reprograms the neuronal epigenome by correcting alterations in gene expression that contribute to the progression of the disease.
Source: https://medicalxpress.com/news/2026-03- ... emory.html
Source: https://medicalxpress.com/news/2026-03- ... emory.html